Autism drug CM-AT by Curemark reaches final phase of human studies

CM-AT, a drug to treat autism by Curemark, is currently in late phase clinical trials.

Curemark, LLC is now enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at ten sites across US.

Curemark’s Phase III trials for CM-AT encompass 12 sites nationally with a total 170 children.

“We have six new trial sites that are now active and recruiting patients – New York, Philadelphia, Houston, Indianapolis, Columbus and Shreveport. These are in addition to the four that we announced had opened enrollment in October and November,” stated Dr. Joan Fallon, Curemark founder and CEO.

Curemark anticipates that the remaining sites will be initiating enrollment soon, he added.

CM-AT is based on research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.

The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.

CM-AT will be one of the first therapies to address the underlying physiology of autism, rather than just treat its symptoms.

The number of children affected by autism is higher than originally thought, according to New data released in December by the U.S. Centers for Disease Control and Prevention (CDC).

Autism affects 1 in 110 children.

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies.